Inclusig Ponatinib Tablets

$980.00$1,200.00

Ponatinib 15mg For Sale

Ponatinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors. Ponatinib is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia

Description

Buy Inclusig Ponatinib Tablets Online

Ponatinib tablet is used to treat certain types of blood cancer (chronic myelogenous leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors. Inclusig 10 mg, 15 mg, 30 mg, and 45 mg tablets are available for oral administration.

Is ICLUSIG right for you?

ICLUSIG is a prescription medicine used to treat adults who have:

  • Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    • in combination with chemotherapy in newly diagnosed Ph+ ALL*
    • alone in adults with Ph+ ALL who cannot receive any other kinase inhibitor medicines or who have a specific type of abnormal gene (T315I-positive) Ph+ ALL
  • Chronic Myeloid Leukemia (CML)
    • chronic phase CML who did not tolerate or no longer benefit from treatment with at least 2 prior kinase inhibitor medicines
    • accelerated phase or blast phase CML who cannot receive any other kinase inhibitor medicines
    • a specific type of abnormal gene (T315I-positive) chronic phase, accelerated phase, or blast phase CML

ICLUSIG is not for use to treat people with newly diagnosed chronic phase CML. RSO Oil

It is not known if ICLUSIG is safe and effective in children.

*ICLUSIG in combination with chemotherapy in newly diagnosed adult patients with Ph+ ALL was approved based on patient responses at 3 months of therapy. There is an ongoing study to confirm results.

 

Additional information

Dosage

15mg – 30 Tablets, 45mg – 30 Tablets

Reviews

There are no reviews yet.

Be the first to review “Inclusig Ponatinib Tablets”

Your email address will not be published. Required fields are marked *